-
With Zero Five-Year Recurrences, the Emerging Tumor Vaccine Brings Hope of Cure
PharmaSources/Wang Hong
January 21, 2021
Undoubtedly, vaccines are one of the most significant milestone inventions in mankind’s fight against diseases, and they have also played an essential role in the treatment of cancer.
-
The tumor disappears after infection with coronavirus! Looking at the “killing cancer with the virus” concept in the oncology field
PharmaSources/Wang Hong
January 21, 2021
The world is full of wonders. According to an article published by a British doctor in the British Journal of Haematology two days ago, a malignant lymphoma patient’s tumor almost disappeared after infection with coronavirus!
-
Data of InnoCare’s Robust Oncology Pipelines Presented at the 2023 AACR Annual Meeting
PharmaSources
April 18, 2023
April 18, 2023,Data of InnoCare’s robust oncology pipelines were presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
-
InnoCare Announces First Subject Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in China
PharmaSources
March 10, 2023
InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in clinical trial of the Company’s B-cell lymphoma-2 inhibitor ICP-248 in China.
-
Immune-Based Therapy Shows Promise Against Advanced Breast Cancers
drugs.com
February 09, 2022
An experimental therapy that harnesses the body's tumor-fighting immune cells...
-
Pre-Op Treatment May Be Advance Against Deadly Liver Cancers
drugs.com
January 28, 2022
When delivering a liver cancer diagnosis, Dr. Thomas Marron pulls no punches: "Liver cancer is one of the deadliest cancers," he tells patients.
-
FDA Accepts Rakuten Medical’s IND Application for Oncology Candidate
contractpharma
December 17, 2021
Will begin clinical studies of RM-1995 photoimmunotherapy in advanced head and neck cancer.
-
NEUVOGEN Appoints Mark W. Frohlich to its Board of Directors and Scientific Advisory Board
firstwordpharma
August 24, 2021
NEUVOGEN, an immunoncology company, is pleased to announce the appointment of Dr. Mark W. Frohlich, MD to its Board of Directors and Scientific Advisory Board ("SAB") effective August 23, 2021.
-
Sapience Therapeutics Enters Into Collaboration with National Cancer Institute (NCI) to Study ST101 Response in Specialized Tumor Models
firstwordpharma
May 31, 2021
Sapience Therapeutics announced today that it has entered into a Collaboration Agreement with the National Cancer Institute of the National Institutes of Health to investigate the activity of its lead clinical program
-
Cabozantinib reduces tumour burden in Phase II neurofibromatosis trial
europeanpharmaceuticalreview
January 18, 2021
Forty percent of neurofibromatosis type 1 patients enrolled in the trial had a >20 percent reduction in tumour burden with cabozantinib.